Stay updated on Nivolumab in ER+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in ER+ Breast Cancer Clinical Trial page.

Latest updates to the Nivolumab in ER+ Breast Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedNew resources and documents have been added to the trial page, including a PDF of the Study Protocol and Statistical Analysis Plan provided by Bristol-Myers Squibb, and sponsor sections for clinical trial recruitment and information. The page also includes a Publications section and expanded keywords, improving access to official materials and related literature.SummaryDifference100%

- Check27 days agoChange DetectedRevision: v3.6.2 is now shown on the page. Several sponsor- and document-related footer items were removed, which changes how study documents and sponsor context are accessed while leaving the core trial details unchanged.SummaryDifference16%

- Check41 days agoChange DetectedThe page adds a recruitment status note and new guidance sections to help users join or understand the study, and updates the revision tag to v3.6.0 while adjusting the Intervention/Treatment heading.SummaryDifference0.1%

- Check48 days agoChange DetectedThe page now displays the latest revision label Revision: v3.5.5, replacing the previous v3.5.4. This indicates a minor update to the page versioning rather than a substantive content change.SummaryDifference0.0%

- Check70 days agoChange DetectedA new revision label v3.5.4 has been added, replacing the previous v3.5.3. This indicates an update to the page's revision history rather than any changes to the study content.SummaryDifference0.0%

- Check91 days agoChange DetectedThis change adjusts how the Chilean Valparaíso location is presented (e.g., region wording) while keeping the same city/address line for that site. It also reflects an automated site version/revision update without altering the study’s scientific or participant-relevant details.SummaryDifference0.2%

Stay in the know with updates to Nivolumab in ER+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in ER+ Breast Cancer Clinical Trial page.